Tairui Investment

Dec 1, 2016

Tweet Qiming Venture Capital has led a US$8 million series A funding round in dMed Co., Ltd., a Chinese clinical contract research organization (CRO), with participation from Tairui Investment and ZAI Laboratory. The company says that it will use the latest proceeds to expedite the expansion of its current team, including assurance and clinical operations professionals, according to an announcement. "Established by a group of people with profound global R&D experience, this company has the potential to become an international brand for providing drug innovation services and solutions," says Nisa Leung, Qiming’s managing partner. dMed was founded in August of 2016 by Dr. Lingshi Tan, formerly the founder and general manager of Pfizer’s Global R&D Center in China. He led the center to become a large organization with over 1,000 professionals. In a short period of time, the company has secured clients including ZAI Laboratory’s PARP inhibitor for ovarian cancer and HUA Medicine’s GKA for diabetes. Both of these companies are Qiming's portfolio companies. "China biopharmaceutical has entered into a historic turning point. Innovation has become the inevitable trend of this evolving industry. Many R&D based biopharmaceutical companies have advanced their innovative products into the clinical development stage. However, this is the stage at which they may face bottlenecks," explains Dr. Tan on his intentions of founding the company. [Please send your news, tips, and feedback to [email protected] ]